Last reviewed · How we verify
Doxycycline Hyclate Enteric-Coated Capsules
Doxycycline is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
Doxycycline is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Used for Bacterial infections including respiratory tract infections, urinary tract infections, and skin infections, Acne vulgaris, Malaria prophylaxis.
At a glance
| Generic name | Doxycycline Hyclate Enteric-Coated Capsules |
|---|---|
| Sponsor | The Third Xiangya Hospital of Central South University |
| Drug class | Tetracycline antibiotic |
| Target | Bacterial 30S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Doxycycline works by blocking the attachment of aminoacyl-tRNA to the bacterial ribosome, preventing peptide chain elongation and ultimately inhibiting bacterial growth. The enteric-coated formulation delays release until the drug reaches the small intestine, reducing gastrointestinal irritation. This broad-spectrum antibiotic is effective against a wide range of gram-positive and gram-negative bacteria, as well as some atypical organisms.
Approved indications
- Bacterial infections including respiratory tract infections, urinary tract infections, and skin infections
- Acne vulgaris
- Malaria prophylaxis
- Lyme disease
Common side effects
- Nausea and vomiting
- Photosensitivity
- Esophageal irritation
- Diarrhea
- Vaginal candidiasis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: